Reported 2 days ago
Intellia Therapeutics, a biotech firm, has seen its stock rise 63% this year, driven by promising gene-editing therapies targeting rare diseases. With two late-stage candidates, lonvoguran ziclumeran and nexiguran ziclumeran, the company aims for significant market opportunities, projecting potential sales of $5 billion and $12 billion, respectively, by 2028. Despite its optimistic outlook and a potential doubling of stock value, analysts caution against overrating the company's sales projections due to inherent risks in biotechnology.
Source: YAHOO